Skip to main content
. 2017 Jun 28;7:4361. doi: 10.1038/s41598-017-04709-2

Figure 7.

Figure 7

DACH1 and CD44 were related to clinical outcomes of breast cancer patients. Meta-analysis of a total of 19 public databases showed that breast cancer patients with higher DACH1 mRNA level tended to have better overall survival (a), relapse-free survival (c), metastasis-free survival (e). On the contrary, patients with higher CD44 mRNA expression had shorter time to death (b) and metastasis (f), but did not acquire statistically significant worse relapse-free survival in comparison to patients with comparatively lower CD44 expression (d).